What is the current Price Target for the Prelude Therapeutics Inc stock?

The average Prelude Therapeutics Inc target price is $2.50. This is 217.58% higher than the current stock price. The highest price target is 408.13%, the lowest is 27.03%. 2 Analysts have issued a price target Prelude Therapeutics Inc 2026 .

How high will the Prelude Therapeutics Inc stock rise?

No reliable answer can be given as to how high the Prelude Therapeutics Inc stock will rise. The performance of stocks, including the Prelude Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Prelude Therapeutics Inc stock today?

The performance of Prelude Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Prelude Therapeutics Inc stock fall?

The decline in Prelude Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Prelude Therapeutics Inc Forecast, price target & analysts

$0.75

4.40% today

Nasdaq, Apr 03, 06:33 pm CET

ISIN

US74065P1012

Symbol

PRLD

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Prelude Therapeutics Inc Target price 2025 - Analyst rating & recommendation

Prelude Therapeutics Inc Classifications & Recommendation:

Buy

50%

Sell

50%

Prelude Therapeutics Inc Price Target

Target Price	$2.50
Price	$0.79
Potential	217.58% register free of charge
Number of Estimates	2

	2 Analysts have issued a price target Prelude Therapeutics Inc 2026 . The average Prelude Therapeutics Inc target price is $2.50. This is 217.58% register free of charge higher than the current stock price. The highest price target is $4.00 408.13% register free of charge , the lowest is $1.00 27.03% register free of charge .
	A rating was issued by 2 analysts: 1 Analysts recommend Prelude Therapeutics Inc to buy, 0 to hold and 1 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Prelude Therapeutics Inc stock has an average upside potential 2026 of 217.58% register free of charge . Most analysts recommend the Prelude Therapeutics Inc stock at Purchase or sale.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1.68	-1.04
	16.83%	38.10%
P/E		negative

1 Analysts have issued a Prelude Therapeutics Inc forecast for earnings per share. The average Prelude Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1.68	16.83%
2025	$-1.04 38.10% Unlock
2026	$-0.43 58.65% Unlock
2027	$-0.29 32.56% Unlock

Current	-0.43	80.28%
2025	-0.76 76.74% Unlock
2026	-1.83 140.79% Unlock
2027	-2.71 48.09% Unlock

Prelude Therapeutics Inc...

Current Prelude Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
Citizens Capital Markets	Locked ➜ Locked	Locked	Mar 12 2025
JMP Securities	Locked ➜ Locked	Locked	Dec 11 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 08 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 28 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 19 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Sep 16 2024
JMP Securities	Locked ➜ Locked	Locked	Sep 16 2024

Analyst Rating	Date
Locked Citizens Capital Markets: Locked ➜ Locked	Mar 12 2025
Locked JMP Securities: Locked ➜ Locked	Dec 11 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 08 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 28 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 19 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Sep 16 2024
Locked JMP Securities: Locked ➜ Locked	Sep 16 2024

Discover more stocks with a high price target

Novo Nordisk 75.12%

Coinbase Global, Inc. 71.30%

BioNTech SE - ADR 48.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now